Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Stay updated with breaking news from Johnson Research Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
/PRNewswire/ -- JTEC Energy, Inc. announced that Dr. Glenn Eisman has joined its Technical Advisory Board. JTEC Energy was formed in 2020 to finish development...
/PRNewswire/ -- JTEC Energy, Inc. announced that Daryl Ludlow has joined its Technical Advisory Board. JTEC Energy was formed in 2020 to finish development and...
/PRNewswire/ -- JTEC Energy and Johnson Energy Storage announced that the companies' founder, Super Soaker inventor Dr. Lonnie Johnson, was inducted into the...
/PRNewswire/ -- JTEC Energy, Inc. announced that it has developed working models of the Johnson Thermo-Electrochemical Converter, an invention that turns waste...